Our mission is to apply our in-depth experience and expertise in clinical research and drug development to lead our clients’ compounds and devices toward regulatory approval.
InClinica is a global clinical CRO that specializes in leading companies through clinical trials. The company originated in 2007, and was subsequently acquired by Velocity Fund Partners, a private equity firm focused on promising opportunities in life sciences and healthcare services.
Our senior management team has more than a century of internal drug development experience.
We have experience in multiple diseases and device technologies, conducted across all stages of clinical trials, in North America, Asia/Pacific, Europe and Latin America.